Can influenza B provoke deep‑vein thrombosis and pulmonary embolism?

Can Influenza B Provoke DVT and PE?

Yes, influenza B infection can provoke deep vein thrombosis (DVT) and pulmonary embolism (PE), though the evidence is stronger for influenza A, particularly H1N1. Severe viral pneumonias, including influenza, create a prothrombotic state that significantly increases VTE risk, particularly in hospitalized patients.

Evidence for Influenza-Associated VTE Risk

Documented Risk Magnitude

• Patients with severe viral pneumonias such as influenza H1N1 demonstrate an 18- to 23-fold higher risk for VTE compared to control patients 1, 2
• This multi-fold increased risk applies specifically to severe pneumonias and acute respiratory syndromes from influenza viruses 1
• One study of influenza H1N1 patients with ARDS found that those receiving therapeutic anticoagulation had 33-fold fewer VTE events than those on prophylactic doses 1

Clinical Case Evidence

• A scoping review identified 58 documented cases of thromboembolic events with laboratory-confirmed influenza A or B, with pulmonary embolism occurring in 36.2% and DVT in 20.6% of cases 3
• Case reports document acute thrombotic vascular events including DVT, PE, and arterial thrombosis complicating influenza-associated pneumonia 4

Mechanistic Considerations

• Acute infection serves as a strong VTE trigger with a 24-fold increased odds ratio, which remains 15-fold elevated even after adjusting for immobilization 5
• The combination of infection and immobilization creates a synergistic effect with a 141-fold increased VTE risk 5
• Influenza infections are associated with procoagulant changes, endothelial damage, and activation of inflammatory and thrombotic cascades 6, 4

Clinical Implications for Management

Risk Stratification

• All hospitalized patients with influenza-associated pneumonia should be considered at increased VTE risk and evaluated for thromboprophylaxis 1, 2
• The risk is particularly elevated in ICU settings, severe pneumonia, and patients with respiratory failure 1
• Consider VTE in patients with influenza who develop unexplained respiratory deterioration, elevated D-dimer (>6 times upper limit of normal), or acute limb symptoms 1, 6

Prophylaxis Recommendations

• Universal thromboprophylaxis with LMWH or UFH should be administered to hospitalized patients with severe influenza pneumonia unless absolute contraindications exist 1, 2
• Standard-dose prophylaxis is appropriate for non-ICU patients, while intermediate-dose LMWH may be considered for critically ill patients 1
• Absolute contraindications include active bleeding and platelet count <25 × 10⁹/L 6

Diagnostic Approach

• Use standard objective testing (CTPA, V/Q scan, Doppler ultrasound) based on clinical suspicion rather than routine screening 1, 2
• Routine screening with D-dimer or ultrasound is not recommended 1, 2
• Symptoms of PE and influenza can overlap significantly, requiring careful clinical evaluation to distinguish respiratory failure from influenza versus PE 3

Important Caveats

Distinguishing Influenza A vs B

While the strongest evidence comes from influenza H1N1 studies, the pathophysiologic mechanisms (endothelial damage, inflammatory cascade activation, procoagulant state) apply to severe viral pneumonias broadly, including influenza B 1, 2. The scoping review included both influenza A and B cases with thromboembolic complications 3.

Severity-Dependent Risk

The VTE risk is most pronounced in patients with severe pneumonia requiring hospitalization, particularly those in ICU settings with ARDS 1. Outpatients with mild influenza likely have minimal increased risk.

Vaccination Safety

Influenza vaccination itself is not associated with increased VTE risk in adults ≥50 years old 7, and one small study found no association between influenza infection and acute PE in an outpatient setting 8. This underscores that the risk is tied to severe infection and hospitalization, not mild illness or vaccination.